Retigabine: Anticonvulsant, Partial seizures, Clinical trial, Food and Drug Administration, European Medicines Agency, Potassium channel opener

Prices from
145.79

Sponsored links

COMPARE ALL WEBSHOPS (1)

Description

Retigabine: Anticonvulsant, Partial seizures, Clinical trial, Food and Drug Administration, European Medicines Agency, Potassium channel opener

Description Description
Product Specifications Product specifications
Related results Related results
Next
Previous

Compare webshops (1)

Sponsored links · Some shops pay us a fee

Sort by:

€ 145.79

Description (0)

Retigabine: Anticonvulsant, Partial seizures, Clinical trial, Food and Drug Administration, European Medicines Agency, Potassium channel opener

Product specifications

Brand OmniScriptum
EAN
  • 9786132769374

Betascript Publishers

Regulatory Requirement: Drug Discovery, Development, Food and Administration, European Medicines Agency, Japan...

€ 108.41
More Information More Info

OmniScriptum

Eplivanserin: Insomnia, Sanofi- Aventis, Food and Drug Administration, European Medicines Agency, 5-...

€ 108.41
More Information More Info

OmniScriptum

Approved Drug: Food and Drug Administration, Pharmaceutical drug, New Application, Clinical trial, discovery

€ 127.10
More Information More Info

OmniScriptum

Certolizumab Pegol: Monoclonal antibodies, UCB (company), Rheumatoid arthritis, Tumor necrosis factor-alpha, Food...

€ 127.10
More Information More Info
Featured Choice
€ 145.79
To Shop